CY1112249T1 - Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου - Google Patents
Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιουInfo
- Publication number
- CY1112249T1 CY1112249T1 CY20111100775T CY111100775T CY1112249T1 CY 1112249 T1 CY1112249 T1 CY 1112249T1 CY 20111100775 T CY20111100775 T CY 20111100775T CY 111100775 T CY111100775 T CY 111100775T CY 1112249 T1 CY1112249 T1 CY 1112249T1
- Authority
- CY
- Cyprus
- Prior art keywords
- amino
- cyanoethenyl
- benzonitrile
- dimethylphenyl
- pyrimidinyl
- Prior art date
Links
- YIBOMRUWOWDFLG-UHFFFAOYSA-N 4-[[4-[4-(2-cyanoethenyl)-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile Chemical compound CC1=CC(C=CC#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- -1 2-cyanoethenyl Chemical group 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Hybrid Cells (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI20043578A MY169670A (en) | 2003-09-03 | 2004-09-02 | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| EP05101467 | 2005-02-25 | ||
| EP05108086.9A EP1632232B3 (en) | 2004-09-02 | 2005-09-02 | Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112249T1 true CY1112249T1 (el) | 2015-12-09 |
Family
ID=38091637
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100775T CY1112249T1 (el) | 2004-09-02 | 2011-08-10 | Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου |
| CY2016051C CY2016051I1 (el) | 2004-09-02 | 2016-12-20 | Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου |
| CY2016050C CY2016050I1 (el) | 2004-09-02 | 2016-12-20 | Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY2016051C CY2016051I1 (el) | 2004-09-02 | 2016-12-20 | Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου |
| CY2016050C CY2016050I1 (el) | 2004-09-02 | 2016-12-20 | Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1632232B3 (enExample) |
| JP (1) | JP4912309B2 (enExample) |
| CN (1) | CN104586850A (enExample) |
| AT (1) | ATE508748T1 (enExample) |
| BR (1) | BRPI0514871A (enExample) |
| CY (3) | CY1112249T1 (enExample) |
| DK (1) | DK1632232T6 (enExample) |
| EA (1) | EA013686B1 (enExample) |
| ES (1) | ES2371442T7 (enExample) |
| FR (2) | FR16C1023I1 (enExample) |
| HK (1) | HK1210029A1 (enExample) |
| HU (2) | HUS1600061I1 (enExample) |
| IL (1) | IL181650A (enExample) |
| LT (2) | LTC1632232I2 (enExample) |
| ME (1) | ME01246B (enExample) |
| MX (1) | MX2007002595A (enExample) |
| NI (1) | NI200700068A (enExample) |
| NO (3) | NO340654B1 (enExample) |
| PT (1) | PT1632232E (enExample) |
| RS (1) | RS51923B2 (enExample) |
| SI (1) | SI1632232T1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| SI1981506T1 (sl) | 2006-01-20 | 2013-08-30 | Janssen R&D Ireland | Dolgoročno zdravljenje infekcije HIV s TCM278 |
| AR065720A1 (es) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| ES2524408T5 (es) * | 2010-11-19 | 2022-04-25 | Gilead Sciences Inc | Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato |
| AP2013006779A0 (en) * | 2011-04-15 | 2013-03-31 | Emcure Pharmaceuticals Ltd | An improved rilpivirine process |
| EP2604593A1 (en) | 2011-12-14 | 2013-06-19 | Sandoz AG | Polymorph of Rilpivirine hydrochloride and its use as antiviral |
| WO2013087794A1 (en) | 2011-12-14 | 2013-06-20 | Sandoz Ag | Polymorph of rilpivirine hydrochloride and its use as antiviral |
| EP2628732A1 (en) * | 2012-02-20 | 2013-08-21 | Sandoz AG | Novel crystalline form of rilpivirine hydrochloride |
| WO2013153161A2 (en) * | 2012-04-11 | 2013-10-17 | Sandoz Ag | Novel polymorph of rilpivirine hydrochloride |
| WO2013153162A1 (en) * | 2012-04-11 | 2013-10-17 | Sandoz Ag | Polymorph of rilpivirine hydrochloride |
| CN103570688B (zh) * | 2012-07-19 | 2016-06-08 | 中国科学院上海药物研究所 | 2，5-二氨甲基吡嗪类化合物、其药物组合物、制备方法和用途 |
| GR1008965B (el) * | 2015-12-02 | 2017-02-28 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα που περιλαμβανει δαρουναβιρη και μεθοδος παρασκευης αυτου |
| RU2616267C1 (ru) * | 2016-01-25 | 2017-04-13 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма индинавира немедленного высвобождения и способ ее получения |
| CN110191704A (zh) * | 2016-10-24 | 2019-08-30 | 爱尔兰詹森科学公司 | 可分散组合物 |
| JP7287906B2 (ja) * | 2017-06-30 | 2023-06-06 | ヴィーブ ヘルスケア カンパニー | 組み合わせ並びにその使用及びそれによる治療 |
| CN114392241B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种利匹韦林片及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307543B1 (en) * | 1998-09-10 | 2001-10-23 | Silicon Image, Inc. | Bi-directional data transfer using two pair of differential lines as a single additional differential pair |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| AU2003266413B2 (en) * | 2002-08-09 | 2009-04-02 | Janssen Pharmaceutica N.V. | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
| WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
| EA011164B1 (ru) * | 2003-02-07 | 2009-02-27 | Янссен Фармацевтика Н. В. | Производные пиримидина для профилактики вич-инфекции |
-
2005
- 2005-09-02 ES ES05108086T patent/ES2371442T7/es active Active
- 2005-09-02 EA EA200700536A patent/EA013686B1/ru active Protection Beyond IP Right Term
- 2005-09-02 MX MX2007002595A patent/MX2007002595A/es active IP Right Grant
- 2005-09-02 DK DK05108086.9T patent/DK1632232T6/da active
- 2005-09-02 PT PT05108086T patent/PT1632232E/pt unknown
- 2005-09-02 RS RS20110355A patent/RS51923B2/sr unknown
- 2005-09-02 SI SI200531339T patent/SI1632232T1/sl unknown
- 2005-09-02 ME MEP-2011-144A patent/ME01246B/me unknown
- 2005-09-02 EP EP05108086.9A patent/EP1632232B3/en not_active Expired - Lifetime
- 2005-09-02 CN CN201510012919.7A patent/CN104586850A/zh active Pending
- 2005-09-02 JP JP2007528886A patent/JP4912309B2/ja not_active Expired - Lifetime
- 2005-09-02 AT AT05108086T patent/ATE508748T1/de active
- 2005-09-02 BR BRPI0514871-5A patent/BRPI0514871A/pt not_active Application Discontinuation
-
2007
- 2007-03-01 IL IL181650A patent/IL181650A/en active IP Right Grant
- 2007-03-01 NI NI200700068A patent/NI200700068A/es unknown
- 2007-04-02 NO NO20071745A patent/NO340654B1/no active Protection Beyond IP Right Term
-
2011
- 2011-08-10 CY CY20111100775T patent/CY1112249T1/el unknown
-
2015
- 2015-11-03 HK HK15110805.7A patent/HK1210029A1/xx unknown
-
2016
- 2016-12-20 LT LTPA2016042C patent/LTC1632232I2/lt unknown
- 2016-12-20 LT LTPA2016043C patent/LTPA2016043I1/lt unknown
- 2016-12-20 HU HUS1600061C patent/HUS1600061I1/hu unknown
- 2016-12-20 CY CY2016051C patent/CY2016051I1/el unknown
- 2016-12-20 HU HUS1600060C patent/HUS1600060I1/hu unknown
- 2016-12-20 CY CY2016050C patent/CY2016050I1/el unknown
- 2016-12-20 FR FR16C1023C patent/FR16C1023I1/fr active Active
- 2016-12-20 FR FR16C1025C patent/FR16C1025I2/fr active Active
-
2017
- 2017-11-21 NO NO2017065C patent/NO2017065I1/no unknown
- 2017-11-21 NO NO2017063C patent/NO2017063I1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112249T1 (el) | Αλας του 4-[[4-[[4-(2-κυανοαιθενυλο)-2,6-διμεθυλοφαινυλο]αμινο]-2-πυριμιδινυλο]αμινο]βενζονιτριλιου | |
| NO2014032I1 (no) | (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl-amino]--2-pyrfmidinyl]-amino]-benzonitril Rilpivirine) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter innbefattende hydrokloridsaltet av Rilpiverine; tenofovir og spesielt tenofovirdisproksilfumatat og emtricitabine. | |
| AR023624A1 (es) | Composiciones farmaceuticas que comprenden un inhibidor de hmg coa reductasa | |
| CY1114428T1 (el) | Διαδικασιες για την παρασκευη του 4- 4- 4-(2-κυανοαιθενυλ)-2,6-διμεθυλφαινυλ)αμινο)-2-πυριμιδινυλ)αμινο βενζονιτριλιου | |
| WO2009007441A3 (en) | Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile | |
| PL1632232T6 (pl) | Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu | |
| WO2010030201A3 (en) | Stable oral pharmaceutical composition containing a pharmaceutically acceptable salt of [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidine-5-yl] (3r, 5s) - 3,5 dihydroxyhept-6- enoic acid | |
| CR9032A (es) | Fumarato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino-2- pirimidinil)amino)benzonitrilo | |
| DE60203890D1 (de) | Apfelsäureadditionssalze von terbinafin | |
| UA92467C2 (ru) | Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила | |
| EA200300771A1 (ru) | Новая соль бензоилгуанидина | |
| ATE460934T1 (de) | Pharmazeutische zubereitungen von ciprofloxacin | |
| CY1105105T1 (el) | Χρηση του διστροντιου αλατος του 2-[ν,ν-δι(καρβοξυμεξυλ) amino]- 3-κυανο-4-καρβοξυμεθυλ-θειοφενο-5-καρβοξυλικου οξεος για τη ληψη φαρμακων που προοριζονται για τη θεραπεια γαστρο-δωδεκαδακτυλικων πονων | |
| HRP20110563T1 (en) | Salt of 4[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | |
| ATE424399T1 (de) | Pharmazeutische zusammensetzungen von risperidon in wässriger lösung |